SLC5A2 and diabetes mellitus: Therefore, to avoid the unfavorable decrease in muscle mass, the administration of SGLT2 inhibitors should be carefully considered in patients with diabetes who are at a high risk for sarcopenia, especially in elderly patients with diabetes.